In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Endocyte, Inc.. Trade Record

NASDAQ:ECYT Endocyte, Inc. stock gains 25.11% Exit May 25, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart ECYT May 2, 2018, priceSeries
About Endocyte, Inc.

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.

Trade Information
Trade Type
LONG
ReliabilityScore™
97.06
Entry Date
May 2, 2018
Entry Price
10.34
Sell Date
May 25, 2018
Sell Price
12.94
Net Gain
25.11%
Hold Time
17 Trading Days